Conditions: Carcinoma, Non Small Cell Lung
Keywords: Carcinoma, non small cell lung Second line Third line
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 80
Healthy volunteers: no

Brief summary:
The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.

Detailed description:
The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.

Secondary objectives include:

* To compare response rate of patients in both treatment arms
* To compare overall survival of patients in both treatment arms
* To compare toxicity in both treatment arms
* To determine whether the survival benefit from suramin is associated with reduced M-phase entry in peripheral blood lymphocytes

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Docetaxel intervention 2: Suramin intervention 3: Docetaxel
Intervention descriptions: intervention 1: IV over 60 minutes, 75 mg/m2 intervention 2: IV over 30 minutes intervention 3: IV over 60 minutes. 56 mg/m2

Protocol document: